GenMark Diagnostics, Inc (GNMK) Expected to Earn FY2018 Earnings of ($0.76) Per Share
GenMark Diagnostics, Inc (NASDAQ:GNMK) – William Blair dropped their FY2018 EPS estimates for shares of GenMark Diagnostics in a report released on Wednesday. William Blair analyst B. Weinstein now forecasts that the medical equipment provider will earn ($0.76) per share for the year, down from their previous forecast of ($0.73). William Blair also issued estimates for GenMark Diagnostics’ FY2019 earnings at ($0.47) EPS.
GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.26) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.26). The business had revenue of $16.02 million during the quarter, compared to analyst estimates of $15.82 million. GenMark Diagnostics had a negative net margin of 117.77% and a negative return on equity of 91.14%.
Shares of GenMark Diagnostics (NASDAQ GNMK) opened at $4.27 on Friday. The company has a quick ratio of 2.77, a current ratio of 3.44 and a debt-to-equity ratio of 0.29. The stock has a market cap of $249.15, a price-to-earnings ratio of -3.50 and a beta of 0.99. GenMark Diagnostics has a 12 month low of $3.63 and a 12 month high of $13.67.
A number of hedge funds have recently bought and sold shares of GNMK. TIAA CREF Investment Management LLC lifted its holdings in GenMark Diagnostics by 0.8% in the second quarter. TIAA CREF Investment Management LLC now owns 168,888 shares of the medical equipment provider’s stock worth $1,998,000 after purchasing an additional 1,268 shares during the period. Ameriprise Financial Inc. lifted its holdings in GenMark Diagnostics by 27.1% in the second quarter. Ameriprise Financial Inc. now owns 43,141 shares of the medical equipment provider’s stock worth $510,000 after purchasing an additional 9,196 shares during the period. UBS Asset Management Americas Inc. acquired a new stake in GenMark Diagnostics in the second quarter worth about $277,000. Northern Trust Corp lifted its holdings in GenMark Diagnostics by 9.2% in the second quarter. Northern Trust Corp now owns 630,760 shares of the medical equipment provider’s stock worth $7,462,000 after purchasing an additional 52,984 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in GenMark Diagnostics by 10.9% in the second quarter. Vanguard Group Inc. now owns 2,169,476 shares of the medical equipment provider’s stock worth $25,664,000 after purchasing an additional 212,795 shares during the period.
In related news, insider Hany Massarany sold 17,300 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $4.17, for a total value of $72,141.00. Following the completion of the sale, the insider now owns 722,190 shares of the company’s stock, valued at $3,011,532.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott Mendel sold 6,275 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $4.17, for a total transaction of $26,166.75. Following the completion of the sale, the chief financial officer now directly owns 246,161 shares of the company’s stock, valued at approximately $1,026,491.37. The disclosure for this sale can be found here. Insiders sold 50,322 shares of company stock valued at $218,938 in the last ninety days. Corporate insiders own 7.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/genmark-diagnostics-inc-gnmk-expected-to-earn-fy2018-earnings-of-0-76-per-share/1904862.html.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.